{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:34:59Z","timestamp":1792715699037,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024YFFK0172"],"award-info":[{"award-number":["2024YFFK0172"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024ZYD0090"],"award-info":[{"award-number":["2024ZYD0090"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273812"],"award-info":[{"award-number":["82273812"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515030013"],"award-info":[{"award-number":["2024A1515030013"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010822","name":"Science and Technology Bureau of Chengdu","doi-asserted-by":"publisher","award":["2024-YF05-02599-SN"],"award-info":[{"award-number":["2024-YF05-02599-SN"]}],"id":[{"id":"10.13039\/501100010822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.apsb.2025.11.011","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T21:00:15Z","timestamp":1763326815000},"page":"4083-4102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Engineering selective PI3K\u03b3 inhibitors with antitumor and immunomodulatory potentials"],"prefix":"10.1016","volume":"16","author":[{"given":"Yi","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiru","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaotong","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-8682","authenticated-orcid":false,"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.11.011_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-019-1102-3","article-title":"Harnessing tumor-associated macrophages as aids for cancer immunotherapy","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2025.11.011_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41589-018-0215-0","article-title":"A class of highly selective inhibitors bind to an active state of PI3K\u03b3","volume":"15","author":"Gangadhara","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2025.11.011_bib3","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1016\/j.apsb.2024.06.023","article-title":"Genome-wide pan-GPCR cell libraries accelerate drug discovery","volume":"14","author":"Yang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.11.011_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/dgd.12809","article-title":"A PI3K\u03b3 signal regulates macrophage recruitment to injured tissue for regenerative cell survival","volume":"64","author":"Zhou","year":"2022","journal-title":"Dev Growth Differ"},{"key":"10.1016\/j.apsb.2025.11.011_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.11.011_bib6","article-title":"434 updated clinical data from the melanoma expansion cohort of an ongoing Ph1\/1b study of eganelisib (formerly IPI-549) in combination with nivolumab","volume":"8","author":"Postow","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.11.011_bib7","article-title":"The role of PI3K inhibition in the treatment of breast cancer, alone or combined with immune checkpoint inhibitors","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.apsb.2025.11.011_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejca.2021.08.029","article-title":"PI3K\u03b3\u03b4 inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model","volume":"157","author":"Han","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2025.11.011_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002279","article-title":"Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal","volume":"9","author":"Isoyama","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.11.011_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jare.2024.03.002","article-title":"Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3K\u03b1 inhibitors","volume":"68","author":"Liu","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.apsb.2025.11.011_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2025.11.011_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.11.011_bib13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/acs.bioconjchem.5c00145","article-title":"GSH-responsive heterodimeric dual-targeted nanomedicine modulates EMT to conquer paclitaxel-induced invasive breast cancer metastasis","volume":"36","author":"Chen","year":"2025","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.11.011_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","article-title":"The role of PI3K\u03b3 in the immune system: new insights and translational implications","volume":"22","author":"Lanahan","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.11.011_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/med.21770","article-title":"Targeting phosphatidylinositol 3-kinase gamma (PI3K\u03b3): discovery and development of its selective inhibitors","volume":"41","author":"Zhu","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2025.11.011_bib16","article-title":"Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors","volume":"121","author":"Al","year":"2023","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.apsb.2025.11.011_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201900105","article-title":"Rational design of novel phosphoinositide 3-Kinase Gamma (PI3K\u03b3) selective inhibitors: a computational investigation integrating 3D-QSAR, molecular docking and molecular dynamics simulation","volume":"16","author":"Li","year":"2019","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.apsb.2025.11.011_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00894-019-4129-x","article-title":"Theoretical studies on the selectivity mechanisms of PI3K\u03b4 inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation","volume":"25","author":"Zhu","year":"2019","journal-title":"J Mol Model"},{"key":"10.1016\/j.apsb.2025.11.011_bib19","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1021\/acsmedchemlett.0c00387","article-title":"Discovery of potent and selective 7-azaindole isoindolinone-based PI3K\u03b3 inhibitors","volume":"11","author":"Miles","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.11.011_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41401-023-01166-8","article-title":"Development of PI3K\u03b3 selective inhibitors: the strategies and application","volume":"45","author":"Gu","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.11.011_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1021\/acsmedchemlett.6b00238","article-title":"Discovery of a selective phosphoinositide-3-kinase (PI3K)-\u03b3 inhibitor (IPI-549) as an immuno-oncology clinical candidate","volume":"7","author":"Evans","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.11.011_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13046-024-03133-5","article-title":"Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer","volume":"43","author":"Chen","year":"2024","journal-title":"J Exp Cancer Res"},{"key":"10.1016\/j.apsb.2025.11.011_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116183","article-title":"Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis","volume":"267","author":"Zhang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.11.011_bib24","doi-asserted-by":"crossref","first-page":"117153","DOI":"10.1016\/j.ejmech.2024.117153","article-title":"Hydroxyl-based acid-hypersensitive acetal ester bond: design, synthesis and the application potential in nanodrugs","volume":"283","author":"Wang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.11.011_bib25","article-title":"p-TSA center dot H2O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer","volume":"102","author":"Kumar","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2025.11.011_bib26","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1021\/acs.jmedchem.4c00347","article-title":"Designing small molecule PI3K\u03b3 inhibitors: a review of structure-based methods and computational approaches","volume":"67","author":"Yin","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.11.011_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.apsb.2025.11.011_bib28","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J Chem Theor Comput"},{"key":"10.1016\/j.apsb.2025.11.011_bib29","article-title":"Responsive ROS-augmented prodrug hybridization nanoassemblies for multidimensionally synergitic treatment of hepatocellular carcinoma in cascade assaults","volume":"12","author":"Zeng","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2025.11.011_bib30","first-page":"6066","article-title":"Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.apsb.2025.11.011_bib31","article-title":"Artificial intelligence-curated repository of gene-encoded natural diverse components from herbal medicines","volume":"6","author":"Chen","year":"2025","journal-title":"Innovation"},{"key":"10.1016\/j.apsb.2025.11.011_bib32","article-title":"Emerging paradigms for target discovery of traditional medicines: a genome-wide pan-GPCR perspective","volume":"6","author":"Bi","year":"2025","journal-title":"Innovation"},{"key":"10.1016\/j.apsb.2025.11.011_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40478-020-01029-x","article-title":"Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression","volume":"8","author":"Taylor","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.apsb.2025.11.011_bib34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/CMR.0000000000000473","article-title":"Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics","volume":"28","author":"Gorlov","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.apsb.2025.11.011_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/1538-7445.AM2020-663","article-title":"The dual PI3K-\u03b4\/PI3K-\u03b3 inhibitor duvelisib inhibits signaling and proliferation of solid tumor cells expressing PI3K-\u03b4 and\/or PI3K-\u03b3","volume":"80","author":"Coma","year":"2020","journal-title":"Cancer Res"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525007415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525007415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:17:13Z","timestamp":1783714633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525007415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2211383525007415"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.11.011","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering selective PI3K\u03b3 inhibitors with antitumor and immunomodulatory potentials","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}